<DOC>
	<DOCNO>NCT02432313</DOCNO>
	<brief_summary>Parts 1 2 : Subjects take 1 dose various formulation study product , provide sample pharmacokinetic ( PK ) analysis , least 7 day dos . Part 3 : Subjects take 2-4 dos study product placebo 6 day , plus 1 additional dose , provide sample PK analysis .</brief_summary>
	<brief_title>Safety , Tolerability , Pharmacokinetics Modified Immediate Release Anatabine Citrate Formulations</brief_title>
	<detailed_description>Parts 1 2 : Subjects admit clinic day dose ( Day -1 ) . Subjects fast overnight receive study product morning Day 1 non-randomized manner . Subjects remain onsite 24 h post-dose return clinical unit 36 48 h post-dose provide sample PK analysis . There least 7-day washout regimen . Subject telephone 3-5 day final dose ensure his/her ongoing well-being . Part 3 : Subjects admit clinic day dose ( Day -1 ) . Subjects fast overnight ( Day 1 Day 7 ) receive study product placebo , twice , three time day regimen randomize , double-blind manner . Subjects remain onsite 24 h final dose ( Day 7 ) , leave clinic morning Day 8 return 36 48 h post last-dose provide sample PK analysis . Subject telephone 3-5 day final dose ensure his/her ongoing well-being .</detailed_description>
	<mesh_term>Citric Acid</mesh_term>
	<criteria>negative urinary cotinine normal test value liver function provide inform consent clinically significant abnormal biochemistry , hematology , urinalysis , judge investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>